about
Skin cancer of the head and neck with perineural invasion.Skull base chordoma.Proton therapy for skull base chordomas: an outcome study from the university of Florida proton therapy institute.Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation.Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.Solitary plasmacytoma of bone and soft tissues.Breast-conserving therapy (BCT) for early-stage breast cancer.Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.Proton therapy in the management of non-Hodgkin lymphoma.Adjuvant radiotherapy for cutaneous melanoma.Is there a role for routine use of MRI in selection of patients for breast-conserving cancer therapy?Definitive radiotherapy for prostate cancer.Postprostatectomy radiotherapy for prostate cancer.Erectile dysfunction after radiotherapy for prostate cancer.Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck.Head and neck osteosarcoma.Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression.Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.When is elective pelvic lymph node irradiation indicated in definitive radiotherapy for localized prostate cancer?Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.Submandibular gland-sparing intensity-modulated radiotherapy.Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.Late toxicity following craniospinal radiation for early-stage medulloblastoma.Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.Local control in non-metastatic medulloblastoma.ACR appropriateness criteria follow-up of Hodgkin lymphoma.Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma.ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.Reducing Anesthesia and Health Care Cost Through Utilization of Child Life Specialists in Pediatric Radiation Oncology.Proton Therapy for Pediatric Hodgkin Lymphoma.Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.Breast-conserving therapy in patients with bilateral breast cancer: do today's treatment choices burn bridges for tomorrow?ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.Long-term complications of laparotomy in Hodgkin's disease.Local control and functional results after twice-daily radiotherapy for Ewing's sarcoma of the extremities.Solitary plasmacytoma of bone and soft tissue.Radiotherapy for pediatric brain tumors.
P50
Q33272036-B6BD4B9E-70FE-412E-BB8F-4A542D63416BQ33272255-CE034378-FD05-4C1F-A7F0-391957A008E7Q33275143-E4D15E54-DE66-426A-8B41-39F94355C2BDQ33372739-4F5658B8-D8C3-489F-9E32-CEE7E649E03AQ33919002-22EA3648-D6A8-4FB3-B886-F16B6734BDDBQ35580170-FA8E94A5-CDE7-4D71-8CF3-950543642567Q35616591-DF9873A1-7B98-406D-BFD7-155D39DE9A7DQ36309826-9F9713F6-CC47-42A1-BD42-EFFAB3FBA7F8Q36491663-9956E5D3-86B2-46AF-9C0C-1DE3BF0C9E8AQ36518955-534EE99A-F706-451D-9B2F-B49B5265DA9FQ37080022-36C28383-8191-49D1-927B-570AFC5627DFQ37159841-5BF9E815-08DC-4508-984B-C575FFD9A28DQ37288324-8318B0A3-31AB-466D-80EA-D521CF5B0E34Q37571361-974360D4-D6AF-44CC-9DA7-777AC5F93B1FQ37573342-62DBA2C5-BB13-49C9-8E76-4ED6AC9D4B2EQ37581552-FCB1C2C1-AF6C-4273-A883-A7E3241FEA5EQ37811161-ABA6D47B-F0FF-49F9-88AA-CB38C605BE65Q37811166-3F3CBCBD-BB65-4F0F-9256-23887C3325D1Q37875356-9C4D61FD-765C-4A50-9CA8-E531ADBA13CDQ37947821-AE918C26-581E-436A-9238-B9851DF2AF67Q37975084-07D20F75-532C-4C14-A3B9-038D2D1C4AEEQ37990169-307727F2-DBE5-4D9D-B4AB-95B73315B408Q38034604-97B5E23A-A214-42FE-80AB-6B1000718800Q38087989-CDA809A2-68D7-422A-B8F8-1794A39C6E9BQ38190624-7E445758-A8DD-42F6-A212-2F093B370C9DQ38220127-BB74CA8F-8224-4EB3-9608-620E9E927EF6Q38225901-877F86FC-17C8-4A10-9182-0A10186C71F5Q38256324-CBD1892E-222F-4137-8CFE-2A65F943754EQ38260182-B2056F99-8267-45F7-BB7F-B254B1F945C0Q38638303-17696C2B-9A29-4B24-AFD5-5F7DE1700343Q38864735-B8AF207A-4438-4A52-A2F6-C50D7A7214B1Q38913641-7DC4EC10-ABA3-4366-A88B-BC719C5C8073Q39791791-822F0F19-7049-4500-A8A5-6C4548A230D6Q39846579-80FDCA84-7D8C-419C-B2FB-286256A9740AQ40423213-C3570608-109A-4A8E-B565-81DA774EFD0CQ40575600-40D2B7B3-2E56-4D43-8B0C-001C4CA24BA1Q40762721-EC2A28DE-F9CA-49A3-9B40-2CB2CA8C2455Q41021790-1D66BC54-0C02-4909-B432-CFD26CF3EA7BQ41189142-DE3B62F6-44BA-4C23-8DC8-9C3FD7C40411Q41692231-1485F4EA-0B87-4F28-9565-BBB397934104
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nancy P Mendenhall
@ast
Nancy P Mendenhall
@en
Nancy P Mendenhall
@es
Nancy P Mendenhall
@nl
Nancy P Mendenhall
@sl
type
label
Nancy P Mendenhall
@ast
Nancy P Mendenhall
@en
Nancy P Mendenhall
@es
Nancy P Mendenhall
@nl
Nancy P Mendenhall
@sl
prefLabel
Nancy P Mendenhall
@ast
Nancy P Mendenhall
@en
Nancy P Mendenhall
@es
Nancy P Mendenhall
@nl
Nancy P Mendenhall
@sl
P106
P21
P31
P496
0000-0003-2893-7703